Artal Group’s Kite Pharma, Inc. KITE Stock Holding History

Artal Group’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-150,000	Closed	-$9.24M	–	88
2015 Q4	$9.24M	Hold	150,000	–	–	0.17%	52
2015 Q3	$8.35M	Buy	+150,000	New	+$9.44M	0.19%	50

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Artal Group's KITE Position: Q3 2017 in Review

Artal Group sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 100,000 shares — an estimated $10.4M sold.

Artal Group first reported a position in KITE in Q3 2014 and held it in 12 quarters. The position peaked at $25.9M in Q2 2015. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Artal Group reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Artal Group sold 100,000 Kite Pharma, Inc. shares in Q3 2017, an estimated $10.4M.
Artal Group first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 12 quarters.
Artal Group's Kite Pharma, Inc. position peaked at $25.9M in Q2 2015.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.